TNIB News Alert Tni Biotech Inc (TNIB) 0.1600 12/17/2014 02:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tni Biotech Inc (TNIB) 0.1600 $TNIB

TNI BioTech, Inc. through its wholly owned subsidiary TNI BioTech International Ltd., provides progress report on bridging trial for HIV/AIDS in Nigeria
PR Newswire - Thu Dec 04, 9:00AM CST
TNI BioTech, Inc., (OTC-TNIB) (the "Company" , a specialty pharmaceutical company involved in the manufacture, distribution and marketing of novel, immunotherapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system, announced the finalization of logistics and patient recruitment for the initiation of the Company's 90-day bridging trial in Nigeria of Lodonal(TM) in patients with HIV/AIDS.

TNI BioTech, Inc. Provides Extension of Delivery of Shares to the Transfer Agent
PR Newswire - Mon Dec 01, 1:54PM CST
TNI BioTech, Inc. (OTC-TNIB) (the "Company" received a number of calls from shareholders and brokerage firms requesting that the Company extend the deadline for the delivery of share certificates, by shareholders of record, or beneficial holder lists, by brokerage firms, to the Company's transfer agent. Based on these requests, the Company has agreed to extend the delivery date deadline, which was October 30, 2014, until December 8, 2014.

TNI BioTech, Inc., through its wholly owned subsidiary TNI BioTech International Ltd., announces start of a bridging trial in Nigeria for HIV/AIDS
PR Newswire - Thu Oct 30, 9:00AM CDT
TNI BioTech, Inc., (OTC-TNIB) ("TNIB" or the ("Company" , headquartered in Orlando, Florida and Dublin, Ireland, a specialty pharmaceutical company involved in the manufacture, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system, through its wholly owned subsidiary TNI BioTech International Ltd., today announces the initiation of a 90-day bridging trial in Nigeria of Lodonal(TM) in patients with HIV/AIDS.

TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend
PR Newswire - Mon Sep 29, 2:27PM CDT
TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company" , a biotechnology company pioneering the manufacturing both US and Internationally as well as the marketing of innovative therapies for cancer, HIV/AIDS, opportunistic infections and autoimmune diseases in emerging nations, issued a letter to its shareholders from CEO Noreen Griffin The letter follows:

TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible
PR Newswire - Tue Sep 23, 1:31PM CDT
TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company" , a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, today announced that the Depository Trust Company ("DTC" has approved our common stock for DTC's Deposit and Withdrawal at Custodian ("DWAC" service using a Fast Automated Securities Transfer Service ("FAST" transfer agent as the distribution point. The Company's shareholders holding their securities in street name can now transfer their shares electronically after buying or selling on the open market without the extra expense and delay resulting from the redundant process of requesting and transferring physical certificates.

TNI BioTech Announces Results of Annual Shareholders Meeting
PR Newswire - Tue Sep 09, 5:15AM CDT
TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company" , a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, today announced the results of its 2014 annual general meeting of shareholders.

TNI BioTech Inc. Announces First Shipment of Lodonal® to The Republic of Panama and The Republic of Malawi
PR Newswire - Wed Aug 27, 6:09AM CDT
TNI BioTech Inc. (OTCQB: TNIB), ("we" or the "Company" a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, today announced it had received payment and will make its first shipments of Lodonal® to the Republic of Panama and The Republic of Malawi in conjunction with our marketing partner, The Brewer Group, Inc.

TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014
PR Newswire - Mon Aug 18, 9:25AM CDT
TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company" a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, announced today that the Company is providing a second notice of TNI BioTech's annual meeting of September 4, 2014.

TNI BioTech, Inc., Announces an Extension to the Record Date of its wholly owned subsidiary, Cytocom Inc., and Dividend now Set for September 30, 2014
PR Newswire - Thu Aug 14, 12:39PM CDT
TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company" a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, announced today that the Company is extending the record date of the dividend of Cytocom Inc., shares to all shareholders of the Company to September 30th, 2014.

TNI BioTech and Hubei Qianjiang Pharmaceutical Co., Ltd Supplemental Collaborative Agreement
PR Newswire - Wed Aug 13, 7:08AM CDT
TNI BioTech, Inc. (OTC: TNIB) ("TNI" or the "Company" a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, announced today the signing of a supplemental agreement with Hubei Qianjiang Pharmaceutical Co., Ltd (SHSE:600568) ( Qianjiang) China on behalf of Cytocom, TNI BioTech's wholly owed subsidiary. The signing of the supplemental agreement accelerates clinical trial development in both America and China, for IRT-101 ("MENK" . In the hope of moving clinical development forward the parties agreed to the following:

TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card
PR Newswire - Mon Jul 28, 8:00AM CDT
TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" or the "Company" , a biopharmaceutical company focused on the development, marketing and distribution of opioid-related immunotherapies, announced today that it has filed definitive proxy materials with the Securities and Exchange Commission in connection with its 2014 Annual Meeting of Shareholders to be held on Thursday, September 4, 2014, at 10 a.m., East Standard Time. The record date for determining those shareholders eligible to receive notice of, and to vote at, the 2014 Annual Meeting was set as of July 15, 2014.

TNI BioTech, Inc. Establishes New Record Date for Spin-Off Stock Dividend of Cytocom, Inc. Shares
PR Newswire - Mon Jul 14, 2:17PM CDT
TNI BioTech, Inc. - (OTCQB: TNIB) ("TNIB" or the "Company" , a biotechnology company focused on developing innovative, targeted immune therapies, today announced that its Board of Directors has extended the record date of our spin-off of Cytocom, Inc., a subsidiary of TNIB.

TNI BioTech, Inc. Signs Non-Exclusive Distribution Agreement for Lodonal(TM) for Cancer and Receives First Sale in Africa - CORRECTION
PR Newswire - Wed Jun 25, 10:17AM CDT
TNI BioTech, Inc. (OTC-TNIB) ("TNI BioTech" earlier today announced that its pharmaceutical sales division, Airmed Biopharma Limited, ("Airmed" , a wholly owned Irish Company, has signed a non-exclusive distribution agreement with PanAm Global Logistics, Inc. ("PanAm" to market Lodonal(TM).

TNI BioTech, Inc. Signs Non-Exclusive Distribution Agreement for Lodonal(TM) for Cancer and Receives First Sale in Africa
PR Newswire - Wed Jun 25, 7:35AM CDT
TNI BioTech, Inc. (OTC-TNIB) ("TNI BioTech" is pleased to announce that its pharmaceutical sales division, Airmed Biopharma Limited, ("Airmed" , a wholly owned Irish Company, has signed a non-exclusive distribution agreement with PanAm Global Logistics, Inc. ("PanAm" to market Lodonal(TM).

TNI BioTech, Inc. Cancels Proposed Reverse Split of its Common Stock
PR Newswire - Tue Jun 24, 7:00AM CDT
TNI BioTech, Inc. (OTC: TNIB) ("TNI" or the "Company" a biotechnology company pioneering the development of innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, announced today that its Board of Directors had passed a resolution cancelling the previously announced 9:10 reverse split of its common stock, as per the 14A Information Statement filed with the Securities and Exchange Commission on June 18, 2014, and accordingly will notify all appropriate regulatory authorities that the reverse split is withdrawn.

TNI BioTech, Inc. Files Schedule 14A and Announces Annual Meeting
PR Newswire - Wed Jun 18, 7:00AM CDT
TNI BioTech, Inc. (OTC: TNIB) ("TNI" or the "Company" announced today that it will hold its 2014 Annual Meeting ("Annual Meeting" of Stockholders on August 25, 2014. The Company has fixed the close of business on July 11, 2014 as the record date for determining shareholders entitled to notice of, and to vote at, the Annual Meeting. At the Annual Meeting, stockholders will be asked to elect eight directors to serve until the 2015 annual meeting of stockholders and until their successors have been elected and qualified.

TNI BIOTECH Announces SEC Clearance Of Form 10 Registration Statement And Clears Way To Upgrade To A Higher Exchange
PR Newswire - Tue Feb 11, 2:30PM CST
TNI BioTech Inc., (OTCQB:TNIB) a biotechnology company pioneering the development ofinnovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, today announced that it received notification from the U.S. Securities and Exchange Commission ("SEC" that the SEC has completed its review of the Company's Form 10 registration statement, effectively clearing all comments from the SEC.
GPI: 83.99 (-1.85)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 154

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 136

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 154

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 27

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 129

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 150

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading

Top 5 Most Recently Viewed Articles

Coca-Cola's Emerging Markets Strategy Fuels Long-Term Growth

Updated Category News Views 929

Coca-Cola's Position in Emerging Markets Coca-Cola Co (NYSE: KO) stands as a beacon of growth, with a visionary strategy that highlights both immediate and long-term opportunities. The company has successfully positioned itself in vital markets, particularly in North America and Latin America, which have proven central to its success. According to recent insights from...

Continue Reading
Voda IQ Appoints Armando Piccinini to Drive European Sales

Updated Category News Views 121

Voda IQ dropped some big news back in 2024 when they appointed Armando Piccinini as their European Sales Director. This guy’s got over twenty years under his belt in aquatic conservation, which they clearly hope will ramp up their sales strategy across Europe. But you gotta wonder—are the numbers behind this move really there? Can Experience Translate to Sales Growth?...

Continue Reading
Magnera Corporation to Shine at Upcoming Finance Conference

Updated Category News Views 163

Magnera Corporation's Conference Participation Announcement Magnera Corporation (NYSE: MAGN) has made an exciting announcement regarding its upcoming participation in a significant financial event. The company is set to be a part of the 2025 Bank of America Leveraged Finance Conference, aimed at fostering connections with top institutional investors. The event will take...

Continue Reading
Bullish Momentum Unveiled: Insights on Merck & Co Stocks

Updated Category News Views 180

Exciting Developments in Merck & Co Options Activity Notable investors are expressing strong optimism about Merck & Co. A recent analysis of options trading strategies reveals a wave of activity among traders aiming to capitalize on this potential. Options Trading Overview When reviewing the options history for Merck & Co (NYSE: MRK), we found a total of 33 trades that...

Continue Reading
Gilead Snags Arcellx: A High-Stakes Cancer Gamble Unfolds

Updated Category News Views 195

The Big Play for Cancer Innovation Gilead Sciences Inc. (NASDAQ:GILD) pulled the trigger on a pretty huge acquisition deal, landing Arcellx Inc. (NASDAQ:ACLX) this past Monday for a staggering $115 per share, which gets better with a potential extra $5 per share on a contingent value right. That rings in a hefty total of $7.8 billion—no pocket change, folks. What’s...

Continue Reading